Apimeds Pharmaceuticals US(APUS.US)

Last Updated 19:00:00 ET
longbridge loading

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga_article·
US
ZYBT
-5.64%
US
APUS
-4.70%
US
LGVN
-0.41%
benzinga_article·
US
ZYBT
-5.64%
US
APUS
-4.70%
US
LGVN
-0.41%

12 Industrials Stocks Moving In Wednesday's Intraday Session

benzinga_article·
US
GEO
-0.13%
US
BXC
-11.17%
US
CVGI
-4.56%
benzinga_article·
US
GEO
-0.13%
US
BXC
-11.17%
US
CVGI
-4.56%

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga_article·
US
AVTX
+0.68%
US
APUS
-4.70%
US
TMDX
-3.23%
benzinga_article·
US
AVTX
+0.68%
US
APUS
-4.70%
US
TMDX
-3.23%

Apimeds Names Sungjoon Chae Co-Chief Executive Officer

Tip Ranks·
US
APUS
-4.70%
Tip Ranks·
US
APUS
-4.70%

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program | APUS Stock News

StockTitan·
US
APUS
-4.70%
US
PBE
+0.11%
US
IHE
+1.26%
StockTitan·
US
APUS
-4.70%
US
PBE
+0.11%
US
IHE
+1.26%

Apimeds Pharmaceuticals US FY 2025: Revenue $0 Net loss $6M, EPS $(0.55) — 10-K Summary

TradingView·
US
APUS
-4.70%
TradingView·
US
APUS
-4.70%

Apimeds Pharmaceuticals US | 10-K: FY2025 Revenue: USD 0

Earnings Watch·
US
APUS
-4.70%
Earnings Watch·
US
APUS
-4.70%

Apimeds Secures Forbearance to Support Listing Remediation

Tip Ranks·
US
APUS
-4.70%
Tip Ranks·
US
APUS
-4.70%
© 2026 Longbridge｜Disclaimer